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The IL23R A/Gln381 Allele Promotes IL-23
Unresponsiveness in Human Memory T-Helper 17
Cells and Impairs Th17 Responses in Psoriasis Patients
Paola Di Meglio1,4, Federica Villanova1,5, Luca Napolitano1,5, Isabella Tosi1, Manuela Terranova Barberio2,
Rose K. Mak1, Sarah Nutland3, Catherine H. Smith1, Jonathan NWN Barker1, John A. Todd3 and
Frank O. Nestle1
We and others have shown that the minor, nonconserved allele Gln381 of the Arg381Gln single-nucleotide
polymorphism (rs11209026G4A) of the IL-23 receptor gene (IL23R) protects against psoriasis. Moreover, we have
recently shown impaired IL-23-induced IL-17A production and STAT-3 phosphorylation in Th17 cells generated
in vitro from healthy individuals heterozygous for the protective A allele (GA). However, the biological effect of
this variant has not been determined in homozygous carriers of the protective A allele (AA), nor in psoriatic
patients. Here we expand our functional investigation of the IL23R Arg381Gln gene variant to include AA
homozygous individuals. By using isolated memory CD4þ T cells, we found attenuated IL-23-induced Th17
response in heterozygous individuals. Moreover, we found that AA homozygous individuals were strikingly
unresponsive to IL-23, with minimal or no IL-17A and IL-17F production and failure of human memory Th17 cell
survival/expansion. Finally, IL-23-induced Th17 response was also attenuated in age- and sex-matched GA versus
GG psoriatic patients undergoing systemic treatment. Taken together, our data provide evidence for an allele-
dosage effect for IL-23R Gln381 and indicate that common gene alleles associated with complex diseases might
have biological effects of considerable magnitude in homozygous carriers.
Journal of Investigative Dermatology (2013) 133, 2381–2389; doi:10.1038/jid.2013.170; published online 16 May 2013
INTRODUCTION
Psoriasis is a chronic immune-mediated inflammatory skin
disease, characterized by inflamed scaly plaques, epidermal
hyperplasia, and inflammatory infiltrate (Nestle et al., 2009).
A pathogenic cross talk between innate and adaptive cells,
including keratinocytes, dendritic cells, and T cells, underpins
a dysregulated immune response leading to aberrant epidermal
proliferation (Guttman-Yassky et al., 2011).
Advances have been made in understanding the genetic
basis of the disease, which is inherited as a complex trait
resulting from gene–gene and gene–environment interactions
(Elder et al., 2010). Human leukocyte antigen-C and more than
30 other genes, mainly belonging to the IL-23/T helper (Th)-17
axis, the NF-kB pathway, and the epidermal differentiation
complex, have been identified by means of linkage analysis
and/or by genome-wide association studies as psoriasis
susceptibility genes (Perera et al., 2012; Tsoi et al., 2012).
Insights gleaned from clinical and experimental studies
confirm genetic data supporting a critical role for the IL-23/
Th17 axis in disease pathogenesis (Fitch et al., 2007; Di
Cesare et al., 2009). IL-23 is a heterodimeric IL-23p19/IL-
12p40 cytokine, signals through its heterodimeric IL-23R
complex, and is essential for Th17 cell effector function and
pathogenicity. Th17 cells, producing IL-17A, IL-17F, IL-22,
and IFN-g (Volpe et al., 2009; Boniface et al., 2010), are the
third arm of the adaptive immune system and protect against
bacterial and fungal infections, e.g., infections due to
Staphylococcus aureus and Candida albicans (Miller and
Cho, 2011; Hernandez-Santos and Gaffen, 2012). However,
Th17 cells have been increasingly implicated in autoimmunity
(Miossec et al., 2009).
Increased IL-23 levels, as well as Th17 cells and cytokines,
are present in psoriatic skin (Wilson et al., 2007; Lowes
et al., 2008; Tonel et al., 2010). Experimental models of
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psoriasis-like skin inflammation (Chan et al., 2006; van der
Fits et al., 2009; Rizzo et al., 2011) and selective targeting of
IL-23 in a clinically relevant xenotransplantation model (Tonel
et al., 2010) support the importance of the IL-23/Th17 axis. IL-
23 and Th17 cytokines are downregulated after successful
therapies (Gottlieb et al., 2005; Zaba et al., 2007), and
ustekinumab, secukinumab, ixekizumab, and brodalimumab
monoclonal antibodies directed against IL-12/23p40, IL-17A,
and IL-17RA, respectively, are effective in psoriasis (Griffiths
et al., 2010; Hueber et al., 2010; Leonardi et al., 2012; Papp
et al., 2012).
We and others have shown that genes belonging to the IL-
23 pathway, including IL23R, IL12B, and IL23A, are asso-
ciated with psoriasis (Capon et al., 2007; Cargill et al., 2007;
Nair et al., 2009). One of the most robust and independently
replicated genome-wide association study findings is the
nonsynonymous Arg381Gln single-nucleotide polymorphism
(SNP) (rs11209026G4A) in the IL23R gene (Capon et al.,
2007; Cargill et al., 2007; Nair et al., 2009), with the minor
nonconserved Gln381 allele conferring approximately twofold
greater protection against psoriasis. The IL23R GA/Arg381Gln
SNP also confers an approximately threefold greater
protection against Crohn’s disease (Duerr et al., 2006) and
twofold against ankylosing spondylitis (Rueda et al., 2008),
thus suggesting protection against multiple immune-mediated
diseases by impaired IL-23-induced Th17 responses. We have
recently addressed this hypothesis in a comprehensive
functional characterization of the IL23R GA/Arg381Gln gene
variant in healthy volunteers (Di Meglio et al., 2011). We
showed that although the frequency and overall activity of
Th17 cells were not affected, IL-23-induced Th17 effector
function is indeed impaired in the presence of the protective
381A/Gln allele. In vitro–polarized Th17 cells derived
from IL23R GA/Arg381Gln heterozygous individuals (GA)
displayed significantly reduced IL-23-induced STAT-3 activa-
tion and IL-17A production, as compared with homozygous
carriers of the nonprotective IL23R 381Arg allele (GG).
Our findings have been replicated by two independent
groups, also showing reduced responsiveness to IL-23 in
healthy heterozygous individuals (Pidasheva et al., 2011;
Sarin et al., 2011).
Such functional studies have not been undertaken so far in
either homozygous carriers of the protective 381A/Gln allele
(AA) or in psoriatic patients.
Here we took advantage of the large Cambridge BioRe-
source of volunteers to expand our functional investigation of
the IL23R GA/Arg381Gln SNP in a largely independent cohort
of healthy individuals. Importantly, this cohort included nine
individuals carrying the AA genotype, which, to our know-
ledge, has not been previously functionally investigated. In
keeping with our previous study, we found attenuated IL-23-
induced Th17 response in memory Th cells of GA hetero-
zygous individuals. Moreover, we found that AA homozygous
individuals were strikingly unresponsive to IL-23, with mini-
mal or no IL-17A and IL-17F production and failure of
memory Th17 cell survival/expansion. Finally, to address its
clinical relevance, we investigated the effect of the IL23R GA/
Arg381Gln SNP in psoriatic patients undergoing systemic
treatment and found impaired IL-23-induced Th17 response
in GA heterozygous psoriatic patients.
RESULTS
IL23R A/Gln381 heterozygous and homozygous carriers have
normal Th17 cell development
We have previously shown that the frequency of circulatory
Th17 cells is similar in IL23R GG/Arg381 common homo-
zygous and IL23R GA/Arg381Gln protected heterozygous in
normal healthy individuals (Di Meglio et al., 2011). Here we
sought to confirm and expand these findings in a largely
independent cohort of normal healthy individuals, which
included nine subjects homozygous for the minor A/Gln381
allele (demographics in Supplementary Table S1 online).
Figure 1 a and b shows that in keeping with our earlier study,
the frequency of memory CD4þ T cells producing Th17
signature cytokines IL-17A and IL-17F in response to phorbol
12-myristate 13-acetate (PMA)/ionomycin stimulation did not
differ in the three groups. Frequency of cells producing IFNg
or IL-22, proinflammatory cytokines produced not only by
Th17 cells but also by Th1 and Th22 cells, was also not
affected by the IL23R genotype (Figure 1c and d). Therefore,
we conclude that both heterozygous and homozygous carriers
of the minor IL23R A/Gln381 allele have normal Th17 cell
development, as frequency of circulatory Th17 cell was not
affected. Furthermore, in keeping with our earlier study,
we found no difference either in the frequency of memory
CD4þ IL-23Rþ T cells or in IL-23R surface expression in the
different genetic groups (Supplementary Figure S1 online).
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Figure 1. IL-23R A/Gln381 heterozygous and homozygous carriers have
normal Th17 cell development. Peripheral blood mononuclear cells from
healthy individuals homozygous for the common G allele (GG, green squares),
heterozygous GA (red squares), or homozygous for the protective A (AA, blue
squares) were assayed for intracellular cytokines, following phorbol 12-
myristate 13-acetate (PMA)/ionomycin stimulation for 5 hours. The frequency
of IL-17Aþ (a), IL-17Fþ (b), IFN-gþ (c), and IL-22þ (d) cells within memory
CD4þ gate is shown. Each symbol represents one individual donor.
Horizontal bars represent means (a, c) or medians (b, d). One-way analysis of
variance, followed by Bonferroni post test (a, c) or Kruskal–Wallis test and
Dunn’s multiple-comparison test (b, d), was performed, yielding P40.05 for all
comparisons.
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IL-23R A/Glu381 allele promotes IL-23 unresponsiveness in
human memory Th 17 cells
Next, we sought to test the effect of the IL23R GA/Arg381Gln
SNP in IL-23-mediated Th17 responses. We have previously
shown that in vitro–polarized Th17 cells from GA hetero-
zygous individuals have impaired response to IL-23 with
significantly reduced IL-17A production (Di Meglio et al.,
2011). Here we used a simplified in vitro system in which
IL-23-mediated Th17 responses are induced in memory
CD4þT cells cultured with or without IL-23 in the
presence of TCR stimulation for 72 hours (Supplementary
Figure S1 online). GG homozygous memory Th cells
responded to IL-23 stimulation by secreting Th17 cytokines,
and this secretion was attenuated in GA heterozygous,
although it did not reach statistical significance (D IL-17A
mean: GG 179 pg ml1, from 19 to 473 pg ml1, and GA
110 pg ml1, from  49 to 279 pg ml1; D IL-17F median:
GG 428 pg ml 1, from 351 to 5,002 pg ml1, and GA
534 pg ml1, from  3269 to 4514 pg ml1; Figure 2a and
b). However, IL-23-induced IL-17A and IL-17F production
was nearly abolished in AA homozygous memory Th cells
that were virtually unresponsive to IL-23 stimulation (D IL-
17A mean: AA  41 pg ml 1, from  219 to 66.8 pg ml1,
Po0.001 vs. GG, Po0.05 vs. GA; D IL-17F median:
AA 2,050 pg ml1, from  14,047 to 1,534 pg ml1,
Po 0.05 vs. GG; Figure 2a and b). Neither IFN-g nor IL-22
production in response to IL-23 was affected by the IL23R
genotype, although a downward trend in IL-22 production
was observed in AA homozygous (Figure 2c and d).
A critical role of IL-23/IL-23R signaling in favoring terminal
differentiation, survival, and pathogenicity of effector Th17
cells has been demonstrated (McGeachy et al., 2009).
Therefore, we asked whether the IL23R A/Gln 381 allele
affects cell expansion/survival. To this end, we polyclonally
restimulated memory Th cells previously cultured with or
without IL-23, and determined the frequency of Th17 cells. As
shown in Figure 3a and b, the frequency of IL-17Aþ or IL-
17Fþ memory Th cells from GG homozygous carriers
significantly increased (Po0.05) in the presence of IL-23.
On the contrary, the frequency of IL-17Aþ and IL-17Fþ cells
did not increase in either GA heterozygous or AA homozygous
donors, suggesting impaired IL-23-driven survival/expansion
of memory Th17 cells. Neither frequency of IFNgþ nor IL-
22þ cells was affected by the IL23R genotype (Figure 3).
Taken together, we found that the minor A/Gln 381 allele
modulates responsiveness to IL-23 in human memory Th17
cells, possibly affecting Th17 cell expansion/survival.
Functional investigation of the IL-23R GA/Arg381Gln SNP in
psoriatic patients
Although the genetic association of the IL23R GA/Arg381Gln
SNP with psoriasis has been extensively replicated, its func-
tional investigation has not been undertaken in psoriasis
patients so far.
Therefore, we performed such an investigation in psoriatic
patients, either GG homozygous or GA for the IL23R
GA/Arg381Gln SNP.
First, we sought to determine whether the IL23R GA/
Arg381Gln SNP had any effect on disease severity and age
of onset. We found that neither Psoriasis Area Severity Index,
as measurement of disease severity (median Psoriasis Area
Severity Index GG: 5.8, GA: 5.6; Figure 4a), nor age of onset
(median onset GG: 18, GA: 18, Figure 4b) significantly
differed in a large patients’ cohort having the same median
age. Moreover, there was no statistical difference in the
frequency of cases of severe psoriasis (Psoriasis Area Severity
Index X15) in the two genetic groups (data not shown).
Next, we measured the frequency of circulatory Th17 cells
in peripheral blood mononuclear cells (PBMCs) of age-,
gender-, and treatment-matched psoriasis patients carrying
the two IL23R genotypes (demographics in Supplementary
Table S2 online) and found that the frequency of IL-17Aþ ,
IL-17Fþ , IFNgþ , and IL-22þ Th cells did not differ between
the GG and GA groups (Figure 4c–f). Moreover, no difference
was found in either the frequency of IL-23Rþ memory T cells or
in IL-23R surface expression (Supplementary Figure S3 online).
However, by assessing IL-23-mediated Th17 responses in
memory Th cells of age-, gender-, and treatment-matched
patients (demographics in Supplementary Table S3 online), we
found that GA patients had reduced production of IL-23-
induced cytokines, with significantly reduced IL-17A and
IL-22 (D IL-17A median: GG 151 pg ml1, from 3.2 to
649 pg ml 1, and GA 0.2 pg ml1, from  67 to 75 pg ml1,
Po 0.05; D IL-22 median: GG 892 pg ml1, from 572 to
1,953 pg ml1, and GA 134 pg ml1, from 31 to 1,070 pg
ml1, Po0.05; Figure 5a–d). Moreover, increase of IL-17Fþ
cell frequency upon IL-23 culture was significantly reduced
in GA heterozygous as compared with GG, and a downward
trend was also observed in IL-17Aþ and IL-22þ cell
frequency (Supplementary Figure S2 online, Po0.05), further
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Figure 2. IL-23R A/Glu381 allele promotes IL-23 unresponsiveness in human
memory Th17 cells. Supernatants of memory CD4þ T cells from healthy
individuals homozygous for the common G allele (GG, green dots),
heterozygous GA (red dots), or homozygous for the protective A allele
(AA, blue dots), cultured with or without IL-23 for 72 hours, were assayed for
IL-17A (a), IL-17F (b), IFN-g (c), and IL-22 (d) secretion. Data are shown as
differential cytokine production (D) in cells cultured with versus without
IL-23. Each symbol represents one individual donor. Dotted line denotes D¼ 0.
Horizontal bars represent means (a) or medians (b, c, d). One-way analysis of
variance, followed by Bonferroni post test (a) or Kruskal–Wallis test and Dunn’s
multiple-comparison test (b, c, d), was performed. *Po0.05, ***Po0.001.
P40.05 for all other comparisons.
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suggesting impaired IL-23-driven survival/expansion of
memory Th17 cells.
Finally, we measured IL-17A, IL-17F, IL-22, and IFN-g
and IL-23p19 mRNA levels in psoriasis skin biopsies (demo-
graphics in Supplementary Table S4 online). We found no
significant difference in skin mRNA of any of the cytokines
examined in GA as compared with GG patients (data not
shown), thus suggesting that skin cytokines were not affected
by either the IL23R genotype or the different treatments.
Next, we asked whether there was any correlation between
IL-23p19 levels and those of Th17 cytokines in the skin of
psoriasis patients. We found that although there was a positive
correlation between IL-23p19 and IL-17A levels, as well as IL-
22 mRNA levels, in GG patients (IL-23p19/IL-17A Spearman’s
r¼ 0.4308, Po0.0453; IL-23p19/IL-22 Spearman’s r¼0.4852,
Po0.0258), this correlation was absent in GA patients
(IL-23p19/IL-17A Spearman’s r¼ 0.25, P¼ not significant;
IL-23p19/IL-22 Spearman’s r¼0.214, P¼not significant
Figure 5e and f), suggesting interruption of the IL-23/Th17
axis in the skin of GA carriers. No correlation was found
between IL-23p19 and IL-17F or IFN-g mRNA level in any
genetic group (Figure 5g and data not shown).
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Figure 3. IL-23R A/Glu381 allele impairs IL-23-driven survival/expansion of human memory Th17 cells. Memory CD4þ T cells from healthy individuals
homozygous for the common G allele (GG, green), heterozygous GA (red), or homozygous for the protective A allele (AA, blue), cultured with or without IL-23 for
72 hours, were assayed for intracellular cytokines IL-17A, IL-17F, IFN-g, and IL-22, after phorbol 12-myristate 13-acetate (PMA)/ionomycin stimulation for 6 hours.
(a) Representative dot plots of GG, GA, and AA individual donors. (b) Each connected symbol represents paired samples from one individual donor. Wilcoxon signed
rank test (IL-17A: GG and AA, IL-17F: GA) or paired Student’s t-test (IL-17A: GA, IL-17F:GG, AA) was performed. *Po0.05. P40.05 for all other paired comparisons.
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Taken together, our data suggest that although not affecting
disease severity, the IL23R GA/Arg381Gln SNP still results in
attenuated IL-23 signaling and impaired Th17 response, both
in blood and in the skin of psoriatic patients.
DISCUSSION
The IL23R GA/Arg381Gln SNP, protecting against several
immune-mediated inflammatory disease, such as psoriasis,
Crohn’s disease, and ankylosing spondylitis, is one of the most
replicated and one of the very few that has been functionally
validated (Di Meglio et al., 2011; Pidasheva et al., 2011; Sarin
et al., 2011).
Here we expand our previous functional investigation using
a largely independent cohort of healthy individuals, including
carriers of the AA genotype, which, to our knowledge, has not
been previously functionally investigated, as well as psoriatic
patients. We found attenuated IL-23 signaling in healthy
heterozygous individuals, with impaired Th17 cytokine pro-
duction in memory Th cells. Remarkably, AA homozygous
individuals were unresponsive to IL-23, with minimal or no IL-
17A and IL-17F production and failure of memory Th17 cell
survival/expansion in the presence of IL-23. Moreover, IL-23-
induced Th17 responses were also attenuated in age-, gender-,
and treatment-matched GA versus GG psoriatic patients.
Unlike Mendelian disorders in which rare disease alleles
have major effect, the alleles underlying complex genetic
disorders are relatively common and only modestly contribute
to disease risk, thus hampering their functional investigation.
We and others have recently performed such type of study in
healthy GA heterozygous individuals (Di Meglio et al., 2011;
Pidasheva et al., 2011; Sarin et al., 2011). However, similar
studies have not been undertaken so far in either homozygous
carriers of the protective A allele or in psoriatic patients,
possibly owing to the rare frequency of the AA genotype
(o1% AA homozygous in individuals of Western European
descent, HapMap project, public release number 27) and to
the likely presence of several confounding genetic and
environmental factors in patients. Here we took advantage
of the large Cambridge BioResource of volunteers and
included in our study nine individuals homozygous for the
protective A allele, even though they comprise only 0.36% of
the Cambridge population (Nutland and Todd, unpublished).
In keeping with our previous study, we found no difference
in either the frequency of IL-23Rþ memory Th cells or in
IL-23R surface expression in the different genetic groups also
in this data set. Moreover, we also confirmed that IL-23
signaling has no role in Th17 lineage commitment, as the
frequency of circulating Th17 cells did not differ. However, by
using memory Th cells, we found that AA homozygous
individuals were unresponsive to IL-23, whereas heterozygous
individuals displayed an attenuated response to IL-23,
although not statistically significant as in our earlier study in
polarized Th17 cells (Di Meglio et al., 2011), possibly because
of the different experimental system used. Nevertheless, the
striking allele-dosage effect in IL-23 responsiveness, far
exceeding the relatively small odds ratio conferred by IL23R
GA/Arg381Gln, further supports its protective role in immune-
mediated diseases.
Th17 cells and cytokines are increasingly implicated
as major culprits in autoimmunity as opposed to their
protective role in host immunity against fungal and bacterial
infections (Miossec et al., 2009). Mendelian defects in several
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Th17-related genes, such as IL12b, IL12rb, STAT3, IL17ra,
IL17F, cause severe immunodeficiency, marked susceptibility
to, and recurrence of, bacterial and fungal infections
(de Beaucoudrey et al., 2008; Puel et al., 2011). The lack of
Th17 cytokines observed in these cases impairs neutrophil
recruitment, macrophage activation, and AMP production by
keratinocytes and neutrophils, thus interrupting the cross talk
between adaptive and innate immunity required for full
pathogen clearance. In contrast, the almost complete
ablation of IL-23-induced Th17 response we observed in AA
individuals does not seem to predispose to a significant
increase in recurring fungal infections, as ascertained by a
self-administered questionnaire to our healthy volunteers (data
not shown), suggesting that alternative signals can deliver
adequate Th17 responses. Although limited to a small number
of participants, this finding is clinically relevant in the context
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Figure 5. IL23R A/Glu381 allele reduces IL-23 responsiveness in human memory Th17 cells and interrupts the IL-23/th17 axis in the skin of heterozygous
psoriatic patients. (a) Memory CD4þ T cell supernatants from psoriatic patients homozygous GG (green dots) and heterozygous GA (red dots), cultured with or
without IL-23 for 72 hours, were assayed for IL-17A, IL-17F, IFN-g, and IL-22 secretion. Data are shown as differential cytokine production (D) in cells cultured with
versus without IL-23. Each symbol represents one individual donor. Dotted line denotes D¼ 0. Horizontal bars represent medians. Mann–Whitney test was
performed; *Po0.05. P40.05 for all other comparisons. (b) IL-17A, IL-17F, IL-22, and IL-23p19 mRNA levels in psoriasis skin biopsies, relative to human acidic
ribosomal protein (HuPO), were measured by quantitative reverse-transcriptase–PCR, and Spearman’s correlation between IL-23p19 and IL-17A (top), IL-22
(middle), and IL-17F (bottom) skin mRNA level of GG (left, green dots) or GA (right, red dots) patients was performed.
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of IL-23p19 or IL-23R targeting in immune-mediated
diseases, and is in line with the long-term safety data for
anti-IL-12/23p40 showing no increased susceptibility to
infections (Papp et al., 2013). Interestingly, a study asses-
sing the prognostic significance of genetic variants in the
IL-23/Th17 axis for the outcome of T cell–depleted
allogeneic stem cell transplantation found that the donor
IL23R GA/Arg381Gln genotype was associated with
decreased risk of fungal infections and improved patient
overall survival, although increased risk of cytomegalovirus
infections was detected (Carvalho et al., 2010).
To our knowledge, the functional effect of the IL23R
Arg381Gln SNP in individuals affected by psoriasis was
previously unreported. We performed our analysis in age-,
gender-, and treatment-matched patients as the best possible
means of stratification. We are aware that treatment match-
ing may not entirely rule out the effect of therapy on the
parameters analyzed and that the IL23R genotype itself
might affect response to therapy. Nevertheless, we found
attenuated IL-23-induced Th17 responses, with significant
reduction in IL-17A and IL-22 production, as well as
reduced expansion of IL-17Fþ cells in GA patients. The
effect of the IL23R SNP on IL-22 production had not been
appreciated in healthy donors so far (Figures 2d and 3b and
Di Meglio et al., 2011). A possible explanation of why this
effect is found only in psoriasis patients could lie in their
hypersensitivity to IL-23, as suggested by the increased
IL-23R surface expression we have recently shown in
the patients versus healthy control (Tonel et al. 2010).
Moreover, we could detect a positive correlation between
IL-23p19 skin mRNA level and IL-17A and IL-22 in GG, but
not in GA patients, thus implying that the IL-23/Th17 axis
was impaired in protective genotype carriers.
Th17 cytokines are pivotal in psoriasis immunopatho-
genesis. IL-17A and IL-17F stimulate keratinocytes to produce
neutrophil-recruiting chemokines and AMPs; IL-22 induces
epidermal hyperplasia by impairing keratinocyte differentia-
tion and synergizes with IL-17A to induce AMPs (Di Cesare
et al., 2009). Circulating Th17 cells are increased in psoriasis
and are believed to contribute to the systemic inflammatory
disease occurring in patients (Kagami et al., 2010). However,
the attenuation of the IL-23/Th17 axis in the GA patients does
not seem to have an impact on disease severity or time
of onset, most likely because of other genetic and/or
environmental factors involved. Interestingly, Bergboer et al.
(2012) recently reported that IL23R GA/Arg381Gln SNP is
associated with pediatric-onset, but not with adult-onset,
psoriasis in a small-scale study. Moreover, our study has
shown a putative protective effect of IL23R GA/Arg381Gln
SNP in psoriatic patients, raising the question of whether this
could be exploited therapeutically. Despite our increased
understanding of psoriasis pathogenesis, at least 20% of
patients do not respond to anti-tumor necrosis factor and
anti-IL-12/23 therapy, possibly because of underdosing in
overweight patients (Clark and Lebwohl, 2008), but also
suggesting that key pathogenic mechanisms are still ill
understood and the known mechanisms might not apply to
every individual. As genome-wide association studies identify
more psoriasis susceptible genes, the next challenge is not
only their functional validation but most and foremost their
ultimate application to deliver better patient care. With an
increasing number of promising therapeutics aimed at
targeting the IL-23/Th17 axis being developed and tested in
the clinic, the IL23R GA/Arg381Gln SNP is an ideal candidate
to probe as a biomarker for response to treatment. Such studies
would be of relevance also to other immune-mediated
inflammatory disorders, such as Crohn’s disease and
ankylosing spondylitis, owing to shared genetic variants,
immunological pathways, and therapeutic targets.
Taken together, we have confirmed that the IL23R GA/
Arg381Gln SNP confers protection against immune-mediated
inflammatory disease by impairing or ablating IL-23-induced
Th17 response in both healthy volunteers and psoriatic
patients. Therefore, our study paves the way for larger-scale
studies in psoriatic patients, aimed to translate insights gleaned
from ‘‘gene-to-function’’ studies in the healthy population to
stratified medicine approaches delivering the promise of
personalized medicine.
MATERIALS AND METHODS
Subjects
Healthy individuals of European descent were recruited and geno-
typed for the IL23R GA/Arg381Gln variant in house as previously
described (Di Meglio et al., 2011) or through the Cambridge
Bioresource. Functional studies were conducted with 45 donors
(22 men and 23 women; mean age 43 years, range 24–67 years).
Collectively, 174 psoriatic patients of European descent were
recruited at St. John’s Institute of Dermatology and Guy’s and
St. Thomas’ Hospital, after an examination by expert clinicians. In-
house genotyping for IL23R GA/Arg381Gln resulted in the identifica-
tion of 149GG and 25GA patients. Psoriasis Area Severity Index was
obtained for 156 patients; age of disease onset was recorded for 107
patients. Functional studies were conducted with 58 patients
(44 men and 14 women; mean age 44 years, range 25–76 years).
Full demographics of healthy donors and psoriatic patients are in
Supplementary Tables S1–S4 online. Our study was conducted in
accordance with the Declaration of Helsinki Principles, with written
informed consent obtained from each volunteer and approved
by the institutional review board of Guy’s and St. Thomas’ Hospital
(Guy’s Research Ethics Committee, Ethics Committee Code: 06/
Q0704/18).
Isolation and activation of PBMCs
PBMCs were purified by centrifugation on a density gradient (Lym-
phoprep, PAA, Pasching, Austria), frozen down in RPMI 1640 (Life
Technologies, Carlsbad, CA)/11.25% HSA solution (Gemini Bio-
Products, West Sacramento, CA)/10% DMSO (Sigma, St. Louis, MO)
and stored in liquid nitrogen. Cells were thawed and rested overnight
in complete RPMI 1640 medium containing 10% heat-inactivated
human AB serum (Biowhittaker, Walkersville, MD), 50 IU ml 1
penicillin, 50mg ml 1 streptomycin, and 2 mM L-glutamine (all from
Life Technologies) (10% hAB-cRPMI) at 37 1C in humidified 5% CO2/
95% air and then activated with PMA (100 ng ml 1, Sigma)/ionomy-
cin (1mg ml 1, Calbiochem, Darmstadt, Germany) or left unstimu-
lated, in the presence of Golgi Stop (3mM, BD Biosciences, San Jose,
CA) and Brefeldin A (10 ng ml 1, BD Biosciences), for 5 hours.
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Multiparameter flow cytometry
Dead cells were excluded from the analysis by staining with Live Dead
Yellow (Life Technologies). Cells were stained for surface markers,
fixed and permeabilized in BD Human FoxP3 Buffer set (BD Bioscien-
ces), stained for intracellular cytokines, and acquired on a BD SORP
Fortessa (BD Biosciences). Antibodies used are listed in Supplementary
Table S5 online. FACS data analysis was performed using the Diva
(BD Biosciences) and FlowJo (TreeStar, Ashland,OR) software.
Isolation and activation of CD4þCD45ROþRA memory T cells
Memory (CD4þCD45ROþRA ) Th cells were isolated from per-
ipheral blood with Rosette Sep Human CD4þ T cells enrichment
cocktail (StemCells Technologies, Grenoble, France), followed by
centrifugation through Lymphoprep and further purification by
negative selection using magnetic beads (Dynabeads Pan Mouse
IgG, Life Technologies) and anti-CD45RA (Diaclone Gen-Probe
Incorporated, San Diego, CA). Purity of CD4þCD45ROþCD45RA
T cells was over 95%.
Memory Th cells were cultured in duplicate at a density of 5 105
cells per ml in U-bottomed 5-ml tubes in 10% hAB-cRPMI and
activated with anti-CD3/anti-CD28-coated beads (1 bead per 10
cells, Dynabeads CD3/CD28 T cell Expander, Life Technologies) with
or without recombinant human IL-23 (100 ng ml 1, R&D Systems,
Minneapolis, MN) for 72 hours. On day 4, the supernatant was
collected and stored at  80 1C. Cells from duplicated cultures were
pulled together and restimulated in fresh 10% hAB-RPMI medium
with PMA (10 ng ml 1)/ionomycin (500 ng ml 1), in the presence of
Golgi Stop and Brefeldin A, for 6 hours. Multiparameter Flow
Cytometry staining was performed as described for PBMCs.
Determination of cytokine levels
IL-17A and IFN-g cytokine levels in cell supernatants were assayed
using the Milliplex MAP Human Cytokine/Chemokine Kit (Merck
Millipore, Billerica, MA) and acquired on a FlexiMap 3D flow-based
sorting and detection analyzer (Luminex Corporation, Austin, TX). IL-
22 and IL-17F cytokine levels were assayed using commercially
available ELISA kits (R&D Systems).
RNA extraction and quantitative reverse-transcriptase–PCR
Total RNA from psoriasis skin biopsies was obtained using TRIzol
(Life Technologies) and reverse-transcribed into complementary
DNA. IL-23, IL-17A, IL-17F, IL-22, and IFNg expression was assessed
by real-time quantitative reverse-transcriptase–PCR using Taqman
assays (Life Technologies). For each sample, mRNA abundance was
normalized to the amount of human acidic ribosomal protein
(HuPO). Data analysis was performed using the DDCt method; results
are expressed as relative mRNA levels.
Statistical analysis
For PBMC intracellular cytokine production experiments, frequencies
of cytokine-producing cells for each donor belonging to different
genetic groups were assessed for normal Gaussian distribution with
D’Agostino–Pearson omnibus normality test and analyzed by
unpaired two-tailed Student’s t-test or Mann–Whitney’s test, or by
one-way analysis of variance, followed by Bonferroni post test or
Kruskal–Wallis test followed by Dunn’s multiple-comparison test, as
appropriate, by using Prism version 5.0 (GraphPad Software, La Jolla,
CA). For cytokine secretion experiments, cell supernatants were
assayed in duplicate, and mean±SEM was calculated. Results,
expressed as differential cytokine production (D) in cells cultured
with versus without IL-23, were assessed for normal Gaussian
distribution and then analyzed by unpaired two-tailed Student’s
t-test, Mann–Whitney’s test, one-way analysis of variance, followed
by Bonferroni post test or Kruskal–Wallis test followed by Dunn’s
multiple-comparison test, as appropriate. For survival/expansion
experiments of cultured memory Th cells, frequencies of cytokine-
producing cell for each donor belonging to the different genetic
groups were assessed for normal Gaussian distribution and analyzed
by Wilcoxon signed rank test. Spearman’s correlation was used to
correlate skin IL-23 mRNA levels with those of IL-17A, IL-22, IL-17F,
and IFNg. Values of Po0.05 were considered significant.
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